Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy

Nephron - Experimental Nephrology

Volumn 121, Issue 3-4, 2013, Pages

  Kim, Su Mi ^a   Choi, Young Wook ^a   Seok, Hwa Young ^a   Jeong, Kyung Hwan ^b   Lee, Sang Ho ^a   Lee, Tae Won ^b   Ihm, Chun Gyoo ^b   Lim, Sung Jig ^a   Moon, Ju Young ^a  

^a Kyung Hee University College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Diabetic nephropathy; Epithelial mesenchymal transition; Hyperuricemia; TGF 1

Indexed keywords

ALBUMIN; ALLOPURINOL; ALPHA SMOOTH MUSCLE ACTIN; CREATININE; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; URIC ACID; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; SIGNAL TRANSDUCTION; UPREGULATION; URIC ACID BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MICE; MICE, INBRED STRAINS; TRANSFORMING GROWTH FACTOR BETA1; URIC ACID;

EID: 84874763194     PISSN: None     EISSN: 16602129     Source Type: Journal    
DOI: 10.1159/000343567     Document Type: Article

References (31)

1. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190. (Pubitemid 36706063)
2. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB: Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33: 225-234. (Pubitemid 29072223)
3. Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, Roncal C, Johnson RJ, Nakagawa T: Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 2009; 297:F481-F488.
4. Rao GN, Corson MA, Berk BC: Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8608. (Pubitemid 21906552)
5. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293. (Pubitemid 36706079)
6. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226. (Pubitemid 34761303)
7. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from two placebo-controlled studies. Circulation 2002; 105: 2619-2624. (Pubitemid 34596038)
8. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD: Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751. (Pubitemid 30165320)
9. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY: Smad7 inhibits fibrotic effect of TGF-on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464-1472.
10. Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, Nikolic-Paterson DJ, Atkins RC, Lan HY: Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998; 54: 864-876. (Pubitemid 28397404)
11. Okada H, Danoff TM, Kalluri R, Neilson EG: Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273: F563-F574.
12. Zavadil J, Bottinger EP: TGF-and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774.
13. Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y: Glomerular changes in the KKA y/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 2006; 11: 29-35.
14. Moon JY, Tanimoto M, Gohda T, Hagiwara S, Yamazaki T, Ohara I, Murakoshi M, Aoki T, Ishikawa Y, Lee SH, Jeong KH, Lee TW, Ihm CG, Lim SJ, Tomino Y: Attenuating effect of angiotensin-(1-7) on angiotensin iimediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A y/Ta mice. Am J Physiol Renal Physiol;300:F1271-F1282.
15. Katz A, Caramori ML, Sisson-Ross S, Groppoli T, Basgen JM, Mauer M: An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 2002; 61: 2058-2066.
16. Yang J, Liu Y: Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002; 13: 96-107. (Pubitemid 34042016)
17. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-1-induced epithelial-tomesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-968.
18. Yang J, Dai C, Liu Y: Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13: 2464-2477.
19. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M: Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 2002; 61: 1684-1695. (Pubitemid 34437922)
20. Li Y, Yang J, Dai C, Wu C, Liu Y: Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003; 112: 503-516. (Pubitemid 38056335)
21. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897. (Pubitemid 35386908)
22. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
23. Arias AM: Epithelial mesenchymal interactions in cancer and development. Cell 2001; 105: 425-431. (Pubitemid 32520849)
24. Tepass U, Truong K, Godt D, Ikura M, Peifer M: Cadherins in embryonic and neural morphogenesis. Nat Rev Mol Cell Biol 2000; 1: 91-100.
25. Vanderburg CR, Hay ED: E-cadherin transforms embryonic corneal fibroblasts to stratified epithelium with desmosomes. Acta Anat (Basel) 1996; 157: 87-104. (Pubitemid 27207349)
26. Leyva F, Anker SD, Godsland IF, Teixeira M, Hellewell PG, Kox WJ, Poole-Wilson PA, Coats AJ: Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814-1822. (Pubitemid 28556651)
27. Doehner W, Springer J, Landmesser U, Struthers AD, Anker SD: Uric acid in chronic heart failure-current pathophysiological concepts. Eur J Heart Fail 2008; 10: 1269-1270.
28. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ: Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-360. (Pubitemid 35006723)
29. Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV, Sastre J, Vina J: Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002; 51: 1118-1124. (Pubitemid 34438358)
30. Matsumoto S, Koshiishi I, Inoguchi T, Nawata H, Utsumi H: Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radic Res 2003; 37: 767-772. (Pubitemid 36626436)
31. Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, Kelley EE: Febuxostat inhibition of endothelial-bound XO: Implications for targeting vascular ROS production. Free Radic Biol Med 2011; 51: 179-184.